ELK-003 – an opthalmic solution for the treatment of corneal abrasions associated with epidermolysis bullosa
| Biotech website | www.eliksa.com |
| Investment details | $150,000 (£112,000) |
| Start date | April 2025 |
| Research area | Drug therapy |
| Aim | Quality of life change |
| EB sub-type | Dystrophic EB, Junctional EB |
| Investment status | Current |
Investment summary
Eliksa Therapeutics is developing ELK-003, a topical eye drop with the potential to both prevent and treat painful corneal abrasions associated with EB. ELK-003 is derived from amniotic fluid containing essential extracellular matrix proteins, such as collagen 7 and laminin-332, which are critical for maintaining corneal integrity in EB.
In preclinical studies using a mouse model of EB-related corneal abrasions, ELK-003 significantly accelerated healing compared to placebo. Currently, ELK-003 is being tested in a proof-of-concept clinical trial.
Cure EB’s investment, alongside other investors, contributes to the completion of this proof-of-concept (PoC) trial. If successful, PoC trial results would form the basis of a future trial aimed at obtaining regulatory approval in the US and other markets.